KeyBanc Starts Recursion Pharmaceuticals (RXRX) at Overweight

September 15, 2022 4:32 PM EDT Send to a Friend
KeyBanc analyst Scott Schoenhaus initiates coverage on Recursion Pharmaceuticals (NASDAQ: RXRX) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login